6 days ago
Biopharma supply chain plans must navigate contradictory US policies
An employee checks capsules inside a Cadila Pharmaceutical company manufacturing unit in Ahmedabad, India. Not all countries and segments of the biopharmaceutical supply chain will be impacted equally by geopolitical uncertainties. © Reuters
Gopal Nadadur is senior vice president for South Asia, Sam Ide is vice president for China, and Alex Melillo is associate vice president for Japan at The Asia Group, a strategic advisory firm headquartered in Washington, D.C. Gopal is based in New Delhi and Sam and Alex are based in Washington, D.C.
Asia-based biopharmaceutical supply chains are facing a peak period of geopolitically induced uncertainty. Washington is the key source of this upheaval, with industry strategies simultaneously upended by President Donald Trump's tariffs and onshoring policies, national security-focused regulations and pharmaceutical pricing pressure.
